drug

tivozanib hydrochloride

Marketedupdated 2mo ago

by AVEO Pharmaceuticals Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 16, 2028

~2.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Nov 5, 2039method-of-use (U-3476)US 11504365
Nov 5, 2039method-of-use (U-3476)US 11504365
Nov 16, 2028compositionUS 71667222.4y
Nov 16, 2028compositionUS 71667222.4y

FDA exclusivities (2)

Mar 10, 2026NCENew Chemical Entity (5y)
Mar 10, 2026NCENew Chemical Entity (5y)

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

Trials studying tivozanib hydrochloride

phase3A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)completedn=350